INITIAL PSA LEVELS AND PROSTATE CANCER DIAGNOSIS WITH UP TO 7 YEARS FOLLOW-UP IN THE PLCO CANCER SCREENING TRIAL
Amanda Black(St. Elizabeth's Hospital), Gerald L. Andriole(Institut thématique Génétique, génomique et bioinformatique), Paul F. Pinsky(National Cancer Institute), Jerome Mabie(Information Management Services), Lawrence R. Ragard(Westat (United States)), E. David Crawford(University of Colorado Denver), Christine D. Berg(Prevention Group), Thomas Hickey(Information Management Services), Robert L. Grubb, Douglas J. Reding(Ascension), Grant Izmirlian(National Institutes of Health), Thomas Riley(National Cancer Institute), Philip C. Prorok(National Cancer Institute)
Cited by 1
Related Papers
Mortality Results from a Randomized Prostate-Cancer Screening Trial
|New England Journal of Medicine|2009|2.9k
Neoadjuvant Chemotherapy plus Cystectomy Compared with Cystectomy Alone for Locally Advanced Bladder Cancer
|New England Journal of Medicine|2003|2.6k
Probability of Cancer in Pulmonary Nodules Detected on First Screening CT
|New England Journal of Medicine|2013|1.4k
Genome-wide association study of prostate cancer identifies a second risk locus at 8q24
|Nature Genetics|2007|1.1k
Prostate Cancer Screening in the Randomized Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial: Mortality Results after 13 Years of Follow-up
|JNCI Journal of the National Cancer Institute|2012|1.1k